Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison J Moskowitz

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.
Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Cancers|March 29, 2023
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical SettingSerena Zheng, Kanika Gupta, Piyush Goyal, et al.
The Lancet. Oncology|February 17, 2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 studyAlison J Moskowitz, Heiko Schöder, Joachim Yahalom, et al.
Haematologica|August 30, 2023
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluationZachary D Epstein-Peterson, Esther Drill, Umut Aypar, et al.
Leukemia & Lymphoma|July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysisEfrat Luttwak, Edith Tama Robin, Esther Drill, et al.
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
Blood Advances|April 3, 2025
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphomaNiloufer Khan, Parastoo B Dahi, Farhad Khimani, et al.
Blood|December 17, 2025
PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphomaSanjal H Desai, Alison J Moskowitz, Reid W Merryman, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.
Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Cancers|March 29, 2023
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical SettingSerena Zheng, Kanika Gupta, Piyush Goyal, et al.
The Lancet. Oncology|February 17, 2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 studyAlison J Moskowitz, Heiko Schöder, Joachim Yahalom, et al.
Haematologica|August 30, 2023
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluationZachary D Epstein-Peterson, Esther Drill, Umut Aypar, et al.
Leukemia & Lymphoma|July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysisEfrat Luttwak, Edith Tama Robin, Esther Drill, et al.
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
Blood Advances|April 3, 2025
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphomaNiloufer Khan, Parastoo B Dahi, Farhad Khimani, et al.
Blood|December 17, 2025
PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphomaSanjal H Desai, Alison J Moskowitz, Reid W Merryman, et al.
Pageof 10